论文部分内容阅读
目的:探讨血脂康胶囊对冠心病患者的抗氧化及抗炎效果和意义。方法:选取冠心病并且有一定程度的脂代谢紊乱的患者64例,按随机对照原则随机分为A组(32例)及B组(32例),A组给予血脂康胶囊600mg,日2次;B组予洛伐他汀40mg/d,丙氨酸转氨酶或天冬氨酸转氨酶升高超过正常值3倍以上的患者服用剂量减半,即洛伐他汀20mg/d,经治疗或者观察恢复正常后再加到40mg/d。共比8周,检测实验前后的血浆ALT,AST,CK,OX-LDL,CRP及SOD水平。结果:血脂康胶囊可以明显的降低血浆TG,CHOL,LDL水平,并且与对照组差异有显著性意义(P<0.05)。血脂康胶囊可以明显的降低血浆OX-LD,CRP水平,与对照组差异有非常显著性意义(P<0.01),血脂康胶囊可以提高血浆SOD水平优于对照组(P<0.01),而升高ALT,AST,CK的副作用较对照组低(P<0.05)。结论:血脂康胶囊常规剂量不仅有效调脂而安全,并且有一定的抗氧化及抗炎效果。
Objective: To investigate the anti-oxidation and anti-inflammatory effects and significance of Xuezhikang capsule in patients with coronary heart disease. Methods: Sixty-four patients with coronary heart disease and some degree of dyslipidemia were randomly divided into group A (32 cases) and group B (32 cases) according to the randomized control principle. Group A was given Xuezhikang capsule 600 mg twice daily ; B group to lovastatin 40mg / d, alanine aminotransferase or aspartate aminotransferase increased more than 3 times the normal value of patients taking half the dose, namely lovastatin 20mg / d, after treatment or observation returned to normal Then add to 40mg / d. A total of 8 weeks, before and after the test of plasma ALT, AST, CK, OX-LDL, CRP and SOD levels. Results: Xuezhikang capsule can significantly reduce the plasma TG, CHOL, LDL levels, and the difference between the control group was significant (P <0.05). Xuezhikang capsule can significantly reduce the level of plasma OX-LD and CRP, which is significantly different from the control group (P <0.01). Xuezhikang capsule can improve plasma SOD level than the control group (P <0.01) High ALT, AST, CK side effects than the control group (P <0.05). Conclusion: The conventional dosage of Xuezhikang is not only effective for lipid regulation but also has certain anti-oxidant and anti-inflammatory effects.